ECOG-ACRIN EA4181

Primary Category:

Treatment Protocols

Disease Category:

Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma

Status:

Closed

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma

NCT#04115631

EA4181 is closed to accrual, effective March 31, 2023.